Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other Working Capital Changes: 2014-2024

Historic Other Working Capital Changes for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to -$5.8 million.

  • Cartesian Therapeutics' Other Working Capital Changes was N/A to $438,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year change of. This contributed to the annual value of -$5.8 million for FY2024, which is 211.28% down from last year.
  • Per Cartesian Therapeutics' latest filing, its Other Working Capital Changes stood at -$5.8 million for FY2024, which was down 211.28% from $5.3 million recorded in FY2023.
  • Cartesian Therapeutics' Other Working Capital Changes' 5-year high stood at $94.5 million during FY2020, with a 5-year trough of -$64.7 million in FY2022.
  • For the 3-year period, Cartesian Therapeutics' Other Working Capital Changes averaged around -$21.8 million, with its median value being -$5.8 million (2024).
  • In the last 5 years, Cartesian Therapeutics' Other Working Capital Changes skyrocketed by 3,071.44% in 2020 and then plummeted by 211.28% in 2024.
  • Cartesian Therapeutics' Other Working Capital Changes (Yearly) stood at $94.5 million in 2020, then slumped by 148.16% to -$45.5 million in 2021, then plummeted by 42.23% to -$64.7 million in 2022, then spiked by 108.12% to $5.3 million in 2023, then plummeted by 211.28% to -$5.8 million in 2024.